← Search & browse all drugs
CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Lipid modifying agents in combination with other drugs
rosuvastatin, amlodipine and perindopril
C10BX14
Forms & Strengths
- Rosuvastatin/amlodipine/perindopril arginine 5mg/5mg/5mg capsule
- Rosuvastatin/amlodipine/perindopril arginine 10mg/5mg/5mg capsule
- Rosuvastatin/amlodipine/perindopril arginine 10mg/5mg/10mg capsule
- Rosuvastatin/amlodipine/perindopril arginine 20mg/10mg/10mg capsule
Adult Dosing
- One capsule once daily, taken in the morning before a meal
- Dose titration should be performed with individual components before switching to the fixed-dose combination
- Maximum daily dose: Rosuvastatin 20mg / amlodipine 10mg / perindopril arginine 10mg
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established; use is not recommended
Indications
- Replacement therapy for the treatment of essential hypertension and/or dyslipidemia in patients already controlled with the individual monocomponents given concurrently at the same dose level
Mechanism of Action
- Rosuvastatin: Selective and competitive inhibitor of HMG-CoA reductase, halting hepatic cholesterol synthesis
- Amlodipine: Dihydropyridine calcium channel blocker that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral vasodilation
- Perindopril: Angiotensin-converting enzyme (ACE) inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion
Contraindications
- Hypersensitivity to rosuvastatin, amlodipine, other dihydropyridines, perindopril, or any excipient
- Active liver disease or unexplained persistent elevations of serum transaminases exceeding 3x the upper limit of normal
- History of angioedema related to previous ACE inhibitor therapy
- Hereditary or idiopathic angioedema
- Pregnancy and lactation
- Severe hypotension
- Shock (including cardiogenic shock)
- Obstruction of the outflow tract of the left ventricle (e.g., severe aortic stenosis)
- Hemodynamically unstable heart failure after acute myocardial infarction
- Concomitant use with aliskiren-containing patients in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73m2)
- Concomitant use with sacubitril/valsartan
Adverse Reactions
- Dizziness, headache
- Peripheral edema, flushing
- Dry persistent cough
- Myalgia, arthralgia, rhabdomyolysis (rare)
- Hypotension
- Nausea, abdominal pain, dyspepsia, constipation
- Asthenia, fatigue
- Hyperkalemia, increased serum creatinine
- Elevated liver transaminases
Drug Interactions
- Lithium: Increased serum lithium concentration and toxicity with ACE inhibitors
- Potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes: Increased risk of hyperkalemia
- CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): Increased systemic exposure of amlodipine
- CYP3A4 inducers (e.g., rifampicin, St. John's wort): Decreased plasma concentrations of amlodipine
- Cyclosporine: Significantly increases rosuvastatin exposure
- Vitamin K antagonists: Enhanced anticoagulant effect
- Dual blockade of the renin-angiotensin-aldosterone system (RAAS) with ARBs, ACE inhibitors, or aliskiren increases rates of hypotension, hyperkalemia, and renal function changes
- Antacids: Decreased plasma concentration of rosuvastatin when administered simultaneously
Curated Content: Needs Vetting Before Put to Clinical Use